giant cell tumour of bone
Oncology · 2013–2025
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| denosumab Treatment of giant cell tumour of bone (recurrent, unresectable, or resectable but associated with severe morbidity) and bone metastases from solid tumours. | Mar 2025 | Recommended | 3 individuals Rare Cancers Australia |
| denosumab Jubbonti: treatment of osteoporosis (BMD T-score of -2.5 or less) in patients over 70 years old, and established osteoporosis. Wyost: treatment of giant cell… | Nov 2024 | Recommended | input received Medical Oncology Group · Rare Cancers Australia |
| denosumab Treatment of giant cell tumour of bone in adult and skeletally mature adolescent patients who have recurrent, unresectable, or resectable disease associated… | Nov 2013 | Recommended with restriction | unclear |
Who spoke
Rare Cancers Australia · Medical Oncology Group
What the PBS pays
$336M in government benefit over 2024–25, across 1,333,122 services.
This is spend on the medicines considered for this condition, not spend on the disease. A medicine used for several conditions is counted in full under each, so figures across conditions add to more than national PBS expenditure.
| Medicine | Government benefit |
|---|---|
| denosumab | $336.2M |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 2 of 2 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.